



**Vivimed**

Date: 30.05.2023

To

BSE Limited  
P.J.Towers, Dalal Street,  
Mumbai – 400001  
BSE - Code : 532660

National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
NSE- Symbol: VIVIMEDLAB

Dear Sir / Madam,

**Sub: Outcome of Board Meeting- Audited financial results for the quarter and yearended 31 March, 2023**  
**Ref: Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015**

Further to our letter dated 18.05.2023, we would like to inform that the Board of Directors of the Company at its meeting held on Tuesday, 30<sup>th</sup> May, 2023 has approved the Audited Financial Results for the quarter and year ended 31 March, 2023.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Statement of Audited Standalone Financial Results for the quarter and year ended 31 March, 2023 and Auditors' Report thereon;
2. Statement of Audited Consolidated Financial Results for the quarter and year ended 31 March, 2023 and Auditors' Report thereon;
3. Declaration regarding Audit Reports with unmodified opinion; and

The Board Meeting concluded at 23.10 P.M.

This is for your information and records.

Thanking you,

Yours faithfully,  
For Vivimed Labs Ltd

**Santosh Varalwar**  
Managing Director





**Vivimed**

Date: 30.05.2023

To  
BSE Limited  
P.J.Towers, Dalal Street,  
Mumbai – 400001  
BSE - Code : 532660

National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
NSE- Symbol: VIVIMEDLAB

**Sub: Declaration regarding Audit Reports with unmodified opinion  
Ref: Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015**


With reference to the above, we hereby declare that the Statutory Auditors of the Company, have issued Audit Reports with Unmodified Opinion on the Audited Standalone and Consolidated Financial results for the year ended 31 March, 2023.

This is for your information and records.

Thanking you,

Yours faithfully,  
For Vivimed Labs Ltd

**Santosh Varalwar  
Managing Director**



VIVIMED LABS LIMITED

AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2023

Rs. In Million

Sl. No.	Particulars	3 Months Ended			Year Ended	
		31.03.2023 (Audited)	31.12.2022 (Unaudited)	31.03.2022 (Audited)	31.03.2023 (Audited)	31.03.2022 (Audited)
	<b>Income from Operations</b>					
1	Revenue from Operations	397.21	505.59	531.21	1,768.25	2,183.67
	Total revenue from operations	397.21	505.59	531.21	1,768.25	2,183.67
2	Other Income	0.00	0.09	5.60	2.39	12.59
3	Total Revenue (1+2)	397.21	505.68	536.81	1,770.65	2,196.26
4	<b>Expenses</b>					
a	Cost of material consumed	227.54	341.19	311.15	1,078.73	1,429.19
b	Purchases of Stock-in-Trade	-	-	-	-	-
c	Changes in inventories of finished goods work in progress and stock-in-Trade	1,592.46	14.52	11.97	1,607.59	4.85
d	Employee Benefit Expenses	79.17	84.43	85.77	286.97	316.75
e	Finance Costs	80.69	91.64	100.05	352.80	395.27
f	Depreciation and Amortisation Expenses	950.72	38.01	46.63	1,069.10	174.49
g	Other Expenses	135.76	127.09	139.09	676.72	525.06
	Total Expenses	3,066.34	696.88	694.65	5,071.91	2,845.60
5	Profit before tax (3-4)	(2,669.13)	(191.20)	(157.84)	(3,301.26)	(649.34)
6	<b>Tax Expenses</b>					
	Current Taxes	-	-	-	-	-
	Deferred Taxes	(20.65)	-	28.17	(21.17)	28.17
	Total tax expenses	(20.65)	-	28.17	(21.17)	28.17
7	Profit for the period/Year (5-6)	(2,648.48)	(191.20)	(186.01)	(3,280.08)	(677.51)
	<b>Other Comprehensive Income</b>					
	Items that will not be reclassified to profit or loss, net of tax	40.52	-	5.59	40.52	5.59
	Items that will be reclassified to profit or loss, net of tax	-	-	-	-	-
	Total other comprehensive income	40.52	-	5.59	40.52	5.59
9	Total comprehensive income (7+8)	(2,607.96)	(191.20)	(180.43)	(3,239.57)	(671.93)
10	Paid up Equity Share Capital	165.83	165.83	165.83	165.83	165.83
11	Other equity	-	-	-	-	-
12	Earnings per Share (before Extraordinary Items) (of Rs2/- each)					
(a)	Basic	(31.94)	(2.31)	(2.24)	(39.56)	(8.17)
(b)	Diluted	(31.01)	(2.24)	(2.18)	(38.40)	(7.93)

NOTES

- The above standalone financial results of Vivimed Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on May 30, 2023. The statutory auditors of the Company have carried out Audit on standalone financial results and expressed an unmodified conclusion thereon.
- These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("IND AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- The Financial results are prepared in accordance with the Indian Accounting standards (IndAS) as prescribed under section 133 of the companies Act, 2013 read with the companies (Indian Accounting Standards) Rules, 2015 (as amended). In line with provisions of Ind AS 108 Operating segments, the Company has primarily two segments "speciality chemicals" and "Pharma" and accordingly considered under reportable segments by the Company.
- Defaulted in repayment of Loans Outstanding:  
The Company has defaulted in repayment of dues to Banks and Financial institution amounting to Rs. 3,762.80 million as on 31.03.2023 as per books of Account. An amount of Rs. 352.80 million has been accounted as Provision for interest on the loan amount outstanding as on 31.03.2023. All the loan accounts outstanding as on 31.03.2023 are classified as NPA by the banks.
- Impairment of Plant & Machinery  
a) The Company has impaired its Property, Plant and Equipment during the year by an amount of Rs. 892.80 million in respect of Plant & Machinery which is included in Depreciation and Amortisation Expense. Calculation of impairment of PPE has been done by independent valuer, they have identified the indicators of impairment and designed appropriate methodology and valuation model to estimate the recoverable value of assets. Assessed the reasonableness of assumptions relating to revenue growth rate, gross margins, discount rates etc., based on historical results, current developments and future plans of business estimated by management. Accordingly brought the carrying amount of such assets to its estimated value in use.  
b) The Management has not physically verified the property, Plant & Equipment during the year.
- Write off of Inventories  
Inventories are stated at the lower of cost or market. The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. In the current quarter, the company experienced total write-downs and write-offs of Rs. 809.3 million which is inclusive of slow-moving stock and expired stock of no realisable value. This written off inventory is mostly related to the segment Speciality Chemicals. The Written down value of Inventory of Rs. 809.30 million is included in Changes in Inventories of finished goods work in progress and stock-in-Trade.
- Figures for the quarter ended 31.03.2023 and corresponding quarter ended 31.03.2022 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective financial years.
- Capitalization of Capital Work-in-progress  
During the fourth quarter, based on the internal assessment, the Company has capitalised CIVIP in respect of factory Buildings amounting to Rs. 207.14 million. The same amount has been spent on major development of factory units over period of time.
- Investments  
The Investments held in by the company in its foreign subsidiaries, where the business operations are being carried out over past few years but taking into account the management internal assessment and initiatives to be implemented to improve the profitability in the medium to long term, the management of the company is of the view that carrying value of investments are realizable at the value stated in the books.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.

For VIVIMED LABS LIMITED



(SUNIL JOSHI VARALWAR)  
MANAGING DIRECTOR

Place: Hyderabad  
Date: 30.05.2023

**VIVIMED LABS LIMITED**  
**SEGMENT-WISE STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2023**

Particulars	Rs in Million			
	3 Months Ended			Year Ended
	31.03.2023 (Audited)	31.12.2022 (Unaudited)	31.03.2022 (Audited)	31.03.2022 (Audited)
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)				
a.Speciality Chemicals Business	59.96	0.79	31.83	412.04
b.Pharma Business	337.25	504.89	504.97	1,771.63
<b>Total</b>	<b>397.21</b>	<b>505.68</b>	<b>536.81</b>	<b>2,183.67</b>
<b>Less, Inter Segment Revenue</b>				
<b>Net sales / Income from Operations</b>	<b>397.21</b>	<b>505.68</b>	<b>536.81</b>	<b>2,183.67</b>
<b>2.Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>				
a.Speciality Chemicals Business	(1,106.65)	(62.99)	(36.38)	(158.34)
b.Pharma Business	(1,481.78)	(36.57)	(21.42)	(95.74)
<b>Total</b>	<b>(2,588.44)</b>	<b>(99.56)</b>	<b>(57.80)</b>	<b>(254.08)</b>
<b>Less: 1.Interest</b>	<b>80.69</b>	<b>91.64</b>	<b>100.05</b>	<b>355.27</b>
<b>2.Other Un-allocable Expenditure</b>				
<b>3.Un-allocable Income</b>				
<b>Total Profit Before Tax</b>	<b>(2,669.13)</b>	<b>(191.20)</b>	<b>(157.85)</b>	<b>(649.34)</b>
<b>3. Capital Employed</b>				
a.Speciality Chemicals Business	555.67		1,042.14	1,042.14
b.Pharma Business	3,208.55		6,017.53	6,017.53
<b>Total</b>	<b>3,764.22</b>		<b>7,059.67</b>	<b>7,059.67</b>

**Segmental capital employed**


As certain assets of the company including manufacturing facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

  
 For VIVIMED LABS LIMITED  
 SANTOSH VARALWAR  
 MANAGING DIRECTOR

Place : Hyderabad  
 Date : 30.05.2023

Vivimed Labs Limited  
 Standalone Statement of Cash Flows  
 All amounts in Rs Million

	Year Ended 31-03-2023	Year Ended 31-03-2022
<b>I. Cash flows from operating activities</b>		
Profit before tax	(3,301.26)	(643.76)
<i>Adjustments to reconcile profit before tax to net cash flows:</i>		
Depreciation of tangible assets	1,069.10	174.50
Amortisation of intangible assets	-	-
Finance income (including fair value change in financial instruments)	-	-
Finance costs (including fair value change in financial instruments)	352.80	395.27
<b>Operating profit before working capital changes</b>	<b>(1,879.36)</b>	<b>(74.00)</b>
<i>Changes in working capital:</i>		
Adjustment for (increase)/decrease in operating assets		
Trade receivables	104.32	133.12
Inventories	1,607.59	146.15
Loans - current	11.94	-23.04
Other assets - current	(15.89)	(79.28)
Adjustment for increase/(decrease) in operating liabilities		
Trade payables	331.63	45.16
Other financial liabilities	(19.77)	88.55
Other liabilities	(1.53)	4.38
Provisions	6.07	12.02
<b>Cash generated from operations</b>	<b>145.00</b>	<b>253.05</b>
Income taxes paid	-	-
<b>Net cash generated from/(used in) operating activities</b>	<b>145.00</b>	<b>253.05</b>
<b>II. Cash flows from investing activities</b>		
Proceeds from sale/ (Purchase of) property, plant and equipment and intangibles (including capital work in progress), net	(15.99)	(113.37)
Investments made during the year	-	-
Interest received (finance income)	-	-
<b>Net cash used in investing activities</b>	<b>(15.99)</b>	<b>(113.37)</b>
<b>III. Cash flows from financing activities</b>		
Share issue proceeds	-	-
Dividend paid	-	-
Proceeds from/(repayment of) long-term borrowings, net	6.18	38.70
Proceeds from/(repayment of) short-term borrowings, net	183.34	224.49
Interest paid	(352.80)	-395.27
<b>Net cash provided by financing activities</b>	<b>(163.28)</b>	<b>(132.08)</b>
<b>Net increase in cash and cash equivalents (I+II+III)</b>	<b>(34.27)</b>	<b>7.62</b>
Cash and cash equivalents at the beginning of the year	67.77	60.15
<b>Cash and cash equivalents at the end of the year (refer note below)</b>	<b>33.48</b>	<b>67.77</b>
<b>Note:</b>		
Cash and cash equivalents comprise:		
Cash on hand	1.17	0.03
Balances with banks:		
- in current accounts	32.31	67.74
	<b>33.48</b>	<b>67.77</b>



**VIVIMED LABS LIMITED**  
**AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2023**


Rs. In Million

Sl. No.	Particulars	3 Months Ended			Year Ended	
		31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Income From Operations					
	Revenue from operations	370.30	557.40	611.32	1,870.99	2,372.87
	Total revenue from operations	370.30	557.40	611.32	1,870.99	2,372.87
2	Other Income	6.83	0.53	5.71	9.68	12.70
3	Total Revenue (1+2)	377.13	557.93	617.03	1,880.68	2,385.57
4	Expenses					
a	Cost of material consumed	227.12	358.93	365.12	1,099.52	1,529.98
b	Purchases of Stock-in-Trade	0.59	7.43	-	8.01	-
c	Changes in inventories of finished goods work in progress and stock-in-Trade	1,592.46	14.52	11.97	1,607.59	4.85
d	Employee Benefit Expenses	58.18	94.71	96.84	326.67	362.22
e	Finance Costs	55.19	92.18	100.56	359.03	397.60
f	Depreciation and Amortisation Expenses	959.23	40.16	49.48	1,084.07	182.82
g	Other Expenses	104.88	133.12	148.22	702.29	556.43
	Total Expenses	3,057.65	741.05	772.19	5,187.18	3,033.90
5	Profit before tax (3-4)	(2,680.52)	(183.12)	(155.17)	(3,306.51)	(648.33)
6	Tax expenses					
	Current Taxes	-	-	-	-	-
	Deferred Taxes	(20.65)	-	28.17	(21.17)	28.17
	Total tax expenses	(20.65)	-	28.17	(21.17)	28.17
7	Profit for the period/Year before non-controlling interest (5-6)	(2,699.87)	(183.12)	(183.34)	(3,285.33)	(676.50)
	Non-controlling interest					
9	Profit for the period/year (7-8)	(2,699.87)	(183.12)	(183.34)	(3,285.33)	(676.50)
10	Other comprehensive income					
	Items that will not be reclassified to profit or loss, net of tax	40.05	-	5.59	40.05	5.59
	Items that will be reclassified to profit or loss, net of tax	(0.03)	-	-	(0.03)	-
	Total other comprehensive income	40.02	-	5.59	40.02	5.59
11	Non-controlling interest					
12	Other comprehensive income attributable to shareholders(10+11)	5.59	5.59	5.59	5.59	5.59
	Total comprehensive income attributable to:					
	Shareholders of the Company	(2,654.28)	(183.12)	(177.75)	(3,279.75)	(670.92)
	Non-controlling interest					
	Total Comprehensive income	(2,654.28)	(183.12)	(177.75)	(3,279.75)	(670.92)
13	Paid up Equity Share Capital	165.83	165.83	165.83	165.83	165.83
14	Other equity					
15	Earnings per Share (before Extraordinary Items) (of Rs2/- each) (not annualised)					
	(a) Basic	(32.05)	(2.20)	(2.31)	(39.62)	(8.16)
	(b) Diluted	(31.14)	(2.10)	(2.15)	(38.46)	(7.92)

**NOTES**

- The above unaudited consolidated financial results of Vivimed Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on May 30, 2023. The statutory auditors of the Company have carried out Audit on consolidated financial results and expressed an unmodified conclusion thereon.
- These consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("IND AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- The subsidiaries considered for the consolidated financial statements for the Quarter and Half year ended September 30, 2021 are Fineso Pharma Private Limited, Vivimed Labs USA Inc, Vivimed Holdings Ltd and Vivimed Labs Mauritius Ltd.
- Defaulted in repayment of Loans Outstanding.  
The Company has defaulted in repayment of dues to Banks and Financial institution amounting to Rs. 3,762.80 million as on 31.03.2023 as per books of Account. An amount of Rs. 352.80 million has been accounted as Provision for interest on the loan amount outstanding as on 31.03.2023. All the loan accounts outstanding as on 31.03.2023 are classified as NPA by the banks.
- Impairment of Plant & Machinery  
a) The Company has impaired its Property, Plant and Equipment during the year by an amount of Rs. 892.80 million in respect of Plant & Machinery which is included in Depreciation and Amortisation Expense. Calculation of impairment of PPE has been done by independent valuer, they have identified the indicators of impairment and designed appropriate methodology and valuation model to estimate the recoverable value of assets. Assessed the reasonableness of assumptions relating to revenue growth rate, gross margins, discount rates etc., based on historical results, current developments and future plans of business estimated by management. Accordingly brought the carrying amount of such assets to its estimated value in use.  
b) The Management has not physically verified the property, Plant & Equipment during the year.
- Write off of Inventories  
Inventories are stated at the lower of cost or market. The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. In the current quarter, the company experienced total write-downs and write-offs of Rs. 809.3 million which is inclusive of slow-moving stock and expired stock of no realisable value. This written off inventory is mostly related to the segment Speciality Chemicals. The written down value of Inventory of Rs. 809.30 million is included in Changes in Inventories of finished goods work in progress and stock-in-Trade.
- Figures for the quarter ended 31.03.2023 and corresponding quarter ended 31.03.2022 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter of the respective financial years..
- Capitalization of Capital Work-in-progress  
During the fourth quarter, based on the internal assessment, the Company has capitalised CIVIP in respect of factory Buildings amounting to Rs. 207.14 million. The same amount has been spent on major development of factory units over period of time.
- Investments  
The investments held in by the company in its foreign subsidiaries, where the business operations are being carried out over past few years but taking into account the management internal assessment and initiatives to be implemented to improve the profitability in the medium to long term, the management of the company is of the view that carrying value of investments are realizable at the value stated in the books.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad  
Date : 30.05.2023



For VIVIMED LABS LIMITED

(SANTOSH VARALIVAR)  
MANAGING DIRECTOR

## SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2023

Rs. In Million

Particulars	3 Months Ended			Year Ended	
	31.03.2023	31.12.2022	31.03.2022	31.03.2022	31.03.2022
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)					
a. Speciality Chemicals Business	59.96	0.79	31.83	112.21	412.04
b. Pharma Business	317.18	557.14	585.20	1,768.46	1,960.83
<b>Total</b>	<b>377.13</b>	<b>557.93</b>	<b>617.03</b>	<b>1,880.68</b>	<b>2,372.87</b>
Less, Inter Segment Revenue					
<b>Net sales / Income from Operations</b>	<b>377.13</b>	<b>557.93</b>	<b>617.03</b>	<b>1,880.68</b>	<b>2,372.87</b>
<b>2. Segment Results (Profit) (+) / Loss (-)</b> before tax and interest from each segment					
a. Speciality Chemicals Business	(1,106.65)	(62.99)	(36.38)	(1,274.51)	(158.34)
b. Pharma Business	(1,488.67)	(27.95)	(18.23)	(1,672.97)	(92.39)
<b>Total</b>	<b>(2,595.33)</b>	<b>(90.94)</b>	<b>(54.61)</b>	<b>(2,947.48)</b>	<b>(250.73)</b>
Less: 1. Interest	85.19	92.18	100.56	359.03	397.60
2. Other Un-allocable Expenditure					
3. Un-allocable Income		(183.12)	(155.17)	3,306.51	(648.33)
<b>Total Profit Before Tax</b>	<b>2,680.52</b>	<b>(183.12)</b>	<b>(155.17)</b>	<b>3,306.51</b>	<b>(648.33)</b>
<b>3. Capital Employed</b>					
a. Speciality Chemicals Business	956.05		1,054.92	956.05	1,054.92
b. Pharma Business	7,130.30		7,867.66	7,130.30	7,867.66
<b>Total</b>	<b>5,640.44</b>		<b>8,922.58</b>	<b>8,086.35</b>	<b>8,922.58</b>

**Segmental capital employed**

As certain assets of the company including manufacturing facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

For VIVIMED LABS LIMITED




(SANTOSH VARALWAR)  
MANAGING DIRECTOR

Place : Hyderabad  
Date : 30.05.2023

**Vivimed Labs Limited**  
**Consolidated Statement of Cash Flows**  
All amounts in Rs. Million

	Year Ended 31-03-2023	Year Ended 31-03-2022
<b>I. Cash flows from operating activities</b>		
Profit before tax	(3,306.51)	-642.75
<i>Adjustments to reconcile profit before tax to net cash flows:</i>		
Depreciation of tangible assets	1,084.07	182.82
Amoritsation of intangible assets	-	-
Finance costs (including fair value change in financial instruments)	359.03	397.60
<b>Operating profit before working capital changes</b>	<b>(1,863.41)</b>	<b>(62.32)</b>
<i>Changes in working capital:</i>		
Adjustment for (increase)/decrease in operating assets		
Trade receivables	105.54	201.39
Inventories	1,610.06	149.17
Loans - current	31.50	-44.15
Other assets	(31.49)	(84.46)
Adjustment for increase/(decrease) in operating liabilities		
Trade payables	275.19	76.42
Other financial liabilities	44.52	9.62
Other liabilities	(0.83)	16.65
Provisions	(32.97)	13.09
<b>Cash generated from operations</b>	<b>138.12</b>	<b>275.40</b>
Income taxes paid	-	-
<b>Net cash generated from/(used in) operating activities</b>	<b>138.12</b>	<b>275.40</b>
<b>II. Cash flows from investing activities</b>		
Proceeds from sale/ (Purchase of) property, plant and equipment and intangibles (including capital work in progress), net	(9.90)	(164.10)
Investments made during the year	-	-
<b>Net cash used in investing activities</b>	<b>(9.90)</b>	<b>(164.10)</b>
<b>III. Cash flows from financing activities</b>		
Share issue proceeds	-	-
Movement in non-controlling interest	-	-
Dividend paid & sale of subsidiaries	-	-
Proceeds from/(repayment of) long-term borrowings, net	13.25	69.25
Proceeds from/(repayment of) short-term borrowings, net	183.34	224.56
Interest paid	(359.03)	-397.60
<b>Net cash provided by financing activities</b>	<b>(162.44)</b>	<b>(103.79)</b>
<b>Net increase in cash and cash equivalents (I+II+III)</b>	<b>(34.22)</b>	<b>7.53</b>
Cash and cash equivalents at the beginning of the year	71.84	64.31
<b>Cash and cash equivalents at the end of the year (refer note below)</b>	<b>37.62</b>	<b>71.84</b>
<b>Note:</b>		
<b>Cash and cash equivalents comprise:</b>		
Cash on hand	1.17	0.11
Balances with banks:		
- in current accounts	36.45	71.73
	<b>37.62</b>	<b>71.84</b>





## Vivimed Labs Limited

## Balance Sheet

All amounts in Rs Million

Particulars	Standalone		Consolidated	
	As At 31-03-2023 (Audited)	As At 31-03-2022 (Audited)	As At 31-03-2023 (Audited)	As At 31-03-2022 (Audited)
<b>ASSETS</b>				
Non current assets				
Property, Plant and Equipment	2,722.34	3,559.29	2,781.75	3,625.66
Intangible assets	706.27	728.77	1,576.40	1,573.29
Capital work in progress	206.65	400.31	206.65	400.31
Financial assets	-	-	-	-
Investments	1,611.36	1,611.36	1,988.21	1,988.21
Deferred tax assets, net	-	-	-	-
Other non-current assets	-	-	7.58	-
<b>Total non current assets</b>	<b>5,246.62</b>	<b>6,299.73</b>	<b>6,560.59</b>	<b>7,587.48</b>
Current assets				
Inventories	783.10	2,390.69	797.60	2,407.66
Financial assets			-	-
Trade receivables	529.57	633.89	768.11	873.65
Cash and cash equivalents	33.48	67.77	37.62	71.84
Loans	30.39	42.33	397.99	429.49
Others	606.16	566.01	606.16	566.01
Current tax assets, net	97.65	106.71	99.19	106.71
Other current assets	595.55	610.74	616.18	617.31
<b>Total current assets</b>	<b>2,675.90</b>	<b>4,418.14</b>	<b>3,322.85</b>	<b>5,072.67</b>
<b>Total assets</b>	<b>7,922.52</b>	<b>10,717.88</b>	<b>9,883.44</b>	<b>12,660.15</b>
<b>EQUITY AND LIABILITIES</b>				
Equity				
Equity share capital	165.83	165.83	165.83	165.83
Instruments entirely equity in nature	-	-	-	-
Other equity	1,167.35	4,406.91	228.40	3,477.03
<b>Total equity</b>	<b>1,333.17</b>	<b>4,572.74</b>	<b>394.23</b>	<b>3,642.86</b>
Non current liabilities				
Financial Liabilities				
Borrowings	619.81	606.13	623.19	609.93
Others	1,621.08	1,628.58	4,423.76	4,412.68
Deferred tax liabilities, net	90.33	111.51	95.15	116.82
Other Non current liabilities	60.32	60.32	60.32	60.32
Provisions	39.51	80.39	43.81	83.63
<b>Total non current liabilities</b>	<b>2,431.05</b>	<b>2,486.93</b>	<b>5,246.22</b>	<b>5,279.72</b>
Current liabilities				
Financial Liabilities				
Borrowings	3,146.62	2,963.28	3,162.47	2,978.88
Trade payables	705.69	374.06	694.13	418.94
Other financial liabilities	98.90	118.67	163.91	119.62
Other current liabilities	13.50	13.50	27.11	25.17
Provisions	10.70	4.26	12.47	5.62
Current tax liabilities	182.91	184.44	182.91	185.68
<b>Total Current liabilities</b>	<b>4,158.31</b>	<b>3,661.87</b>	<b>4,243.00</b>	<b>3,737.58</b>
<b>Total liabilities</b>	<b>6,589.36</b>	<b>6,145.14</b>	<b>9,489.22</b>	<b>9,017.29</b>
<b>Total equity and liabilities</b>	<b>7,922.53</b>	<b>10,717.88</b>	<b>9,883.44</b>	<b>12,660.16</b>





## P C N & ASSOCIATES

CHARTERED ACCOUNTANTS  
Plot No. "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

Independent Auditor's Review Report on the Quarterly and Year to Date Audited Ind AS Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

To  
The Board of Directors  
M/s Vivimed Labs Limited.  
Report on the Audit of the Standalone Financial Results

### Qualified Opinion:

We have audited the accompanying Statement of Audited Standalone Financial Results of M/s Vivimed Labs Limited ("the Company") for the quarter ended 31 March 2023 and the year-to-date results for the period from 01-04-2022 to 31-03-2023 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").


In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. except for the effects of the matters described in the "Basis for Qualified Opinion" section of our report, give a true and fair view in conformity with the recognition and measurement principles generally accepted in Indian of the net loss and other comprehensive income and other financial information for the quarter ended 31 March, 2023 as well as the year-to-date results for the period from 01-04-2022 to 31-03-2023.

### Basis for Qualified Opinion:

- The Company has defaulted in repayment of dues to Banks and Financial institution amounting to Rs. 3,762.80 million as on 31.03.2023. (Refer to Note No. 4 of Financial Results)






## P C N & ASSOCIATES

CHARTERED ACCOUNTANTS  
Plot No. "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

- The Company has impaired its Plant & Machinery during the year by an amount of Rs. 892.80 million. we are unable to comment upon the correctness of Closing balances of PPE and methods employed for calculating the impairment on Plant & Machinery. (Refer to Note No. 5 of Financial Results)
- The company has written down the Inventories amounting to Rs. 809.3 million during the year. In absence of any competent third-party report and valuation method adopted by the management in respect of written down of inventories, and closing balances, we are unable to comment on the discrepancies. (Refer to Note No. 6 of Financial Results)
- In absence of confirmations from the Related parties, we are unable to comment upon the correctness and validity of Related party transactions disclosed in the notes to financial statements with respect to the Investments, Receivables and Payables.
- The Company has capitalized its Capital Work in Progress amounting to Rs. 206.65 million, we are unable to comment upon the correctness of the same. (Refer to Note No. 8 of Financial Results)
- In the absence of fair valuation of the investments, we are unable to comment upon the carrying value and whether any provision for impairment in the value of investments is required. (Refer to Note No. 9 of Financial Results)
- The company has been defaulted in the payment of various undisputed Statutory Dues amounting to Rs. 135.52 million with appropriate authorities.
- As per our opinion, the compliance of Standards on Internal Audit, internal controls/internal audit system pertains to the operations of the company are not commensurate with the size & diversity of the activities of the company and the apparent weakness has been reported to the management for their appropriate measures to be taken in order to strengthen operations of the company.
- The State Bank of India has appointed forensic auditors, the said audit is under progress and the final outcome is yet to come





## **P C N & ASSOCIATES**

CHARTERED ACCOUNTANTS  
Plot No. "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

### **Management's Responsibilities for the Financial Results**


These quarterly financial results as well as the year-to-date financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net Loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.


In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the





## PCN & ASSOCIATES


CHARTERED ACCOUNTANTS  
Plot No. "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.





## P C N & ASSOCIATES

CHARTERED ACCOUNTANTS  
Plot No. "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Results

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The Financial Results include the results for the quarter ended 31<sup>st</sup> march 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For P C N & Associates  
Chartered Accountants  
Firm's Registration No: 016016S

K Gopala Krishna

Partner

M. No. 203605

UDIN: 23203605BGRTTQ4757



Place: Hyderabad

Date: 30-05-2023



## P C N & ASSOCIATES

CHARTERED ACCOUNTANTS  
Plot No. "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

Independent Auditor's Report on the Quarterly and Year to Date Audited Ind AS Consolidated Financial Results of the Holding Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors

M/s Vivimed Labs Limited.

Report on the Audit of the Consolidated Ind AS Financial Results

### Qualified Opinion

We have audited the accompanying Statement of Consolidated Financial Statements of M/s Vivimed Labs Limited ("Holding Company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group"), for the quarter ended 31 March 2023 and for the period from 01-04-2022 to 31-03-2023 being submitted by the "Holding Company" pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/financial information of subsidiaries includes the results of the following entities:

- (a) Finoso Pharma Private Limited.
- (b) Vivimed Labs USA inc.
- (c) Vivimed Holdings Ltd.
- (d) Vivimed Labs Mauritius Ltd

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. except for the effects of the matters described in the "Basis of Qualified Opinion" paragraph of our report, we are unable to conclude as to whether the preparation of the accompanying interim financial information of The Group is appropriate of the consolidated net loss for the quarter ended 31 March, 2023, consolidated Net loss for the year ended 31 March 2023.





## P C N & ASSOCIATES

CHARTERED ACCOUNTANTS  
Plot No. "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499

E-mail : pcnassociates@yahoo.com

### Basis for Qualified Opinion:

- The Company has defaulted in repayment of dues to Banks and Financial institution amounting to Rs. 3,762.80 million as on 31.03.2023. (Refer to Note No. 4 of Financial Results)
- The Company has impaired its Plant & Machinery during the year by an amount of Rs. 892.80 million. we are unable to comment upon the correctness of Closing balances of PPE and methods employed for calculating the impairment on Plant & Machinery. (Refer to Note No. 5 of Financial Results)
- The company has written down the Inventories amounting to Rs. 809.3 million during the year. In absence of any competent third-party report and valuation method adopted by the management in respect of written down of inventories, and closing balances, we are unable to comment on the discrepancies. (Refer to Note No. 6 of Financial Results)
- In absence of confirmations from the Related parties, we are unable to comment upon the correctness and validity of Related party transactions disclosed in the notes to financial statements with respect to the Investments, Receivables and Payables.
- The Company has capitalized its Capital Work in Progress amounting to Rs. 206.65 million, we are unable to comment upon the correctness of the same. (Refer to Note No. 8 of Financial Results)
- In the absence of fair valuation of the investments, we are unable to comment upon the carrying value and whether any provision for impairment in the value of investments is required. (Refer to Note No. 9 of Financial Results)
- The company has been defaulted in the payment of various undisputed Statutory Dues amounting to Rs. 135.52 million with appropriate authorities.
- As per our opinion, the compliance of Standards on Internal Audit, internal controls/internal audit system pertains to the operations of the company are not commensurate with the size & diversity of the activities of the company and the apparent weakness has





## P C N & ASSOCIATES

CHARTERED ACCOUNTANTS  
Plot No. "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com


been reported to the management for their appropriate measures to be taken in order to strengthen operations of the company.

- The State Bank of India has appointed forensic auditors, the said audit is under progress and the final outcome is yet to come

### Management's Responsibilities for the Consolidated Financial Results

These quarterly financial results as well as the year-to-date consolidated financial results have been prepared on the basis of the interim financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and of its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the group or to cease operations, or has no realistic alternative but to do so.





## P C N & ASSOCIATES

CHARTERED ACCOUNTANTS  
Plot No. "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com


The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.

### Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the holding company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained,





## P C N & ASSOCIATES

CHARTERED ACCOUNTANTS  
Plot No. "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com


whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/ financial information of those entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.





## P C N & ASSOCIATES

CHARTERED ACCOUNTANTS  
Plot No. "N Heights"  
Ground Floor, Software Layout Unit  
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499  
E-mail : pcnassociates@yahoo.com

### Other Matter:

- a) The Unaudited financial statements and other financial information of all four subsidiaries of the Holding company included in the statement, whose financial statements comprise total assets, before elimination, of Rs. 7,127.95 million as at March 31, 2023, total Revenue of Rs. 226.88 million and total Loss & total Comprehensive Income of Rs. 5.14 million and 0.10 million respectively for the period from 01-04-2022 to 31-03-2023. The Financial statements / financial information of this companies is unaudited and have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of this subsidiaries, and our report in terms of sub-sections (3) and (11) of section 143 of the Act, in so far it relates to the aforesaid subsidiaries, is based solely on such unaudited financial statements / financial information.

The Consolidated Financial Results include result for the quarter ended 31 March 2023 being the balancing figure between the unaudited figures in respect of the full financial year and the published unaudited year to date figures up to 3<sup>rd</sup> quarter of the current financial year which were subjected to limited review.

For P C N & Associates  
Chartered Accountants  
Firm's Registration No: 016016S

K Gopala Krishna

Partner

M. No. 203605

UDIN: 23203605BGRTTR8667



Place: Hyderabad

Date: 30-05-2023